MRCP Part 2 → Rheumatology
Rheumatology for MRCP Part 2
Rheumatology accounts for roughly 6% of the MRCP Part 2 blueprint.
This bank has 1 item tagged to it.
How much of MRCP Part 2 is rheumatology?
Around 6% of the paper, per MRCP(UK) examination blueprints and regulations. That weighting is why the
DocPasser mock builder samples sections in proportion rather than shuffling everything into one pile —
practising a flat distribution trains you for a paper that does not exist.
Sample rheumatology questions
A 74-year-old woman describes a 3-week history of left temporal headache, scalp tenderness on brushing her hair, and jaw pain when chewing. This morning she noticed transient blurring in the left eye. ESR is 88 mm/hr.
What is the most appropriate immediate action?
-
Start a non-steroidal anti-inflammatory and review in one week
Wrong. NSAIDs do not treat the vasculitis, and a week's review with visual symptoms is far too slow.
-
Start low-dose prednisolone 15 mg daily
Wrong dose. Uncomplicated polymyalgia-type disease may start around 15 mg, but GCA needs 40 to 60 mg, and visual involvement warrants high-dose treatment, often intravenous methylprednisolone.
-
Start high-dose corticosteroids immediately and arrange urgent temporal artery biopsy correct
Correct. Giant cell arteritis with visual symptoms is an ophthalmic emergency. Steroids start at once. Biopsy remains informative for up to about two weeks afterwards, so waiting for histology risks blindness for no diagnostic gain.
-
Arrange temporal artery biopsy and start steroids once histology confirms the diagnosis
Wrong, and the most dangerous option here. Any delay in a patient with amaurosis risks permanent visual loss, which is typically sudden, painless and can become bilateral.
-
Arrange an urgent MRI brain and defer treatment pending the result
Wrong. Imaging does not exclude GCA and the diagnosis is clinical. Deferring steroids for any investigation with visual symptoms is the error being tested.
The point: GCA with any visual symptom: high-dose steroids now, biopsy soon. Add bone and gastric protection at the outset and consider tocilizumab as a steroid-sparing agent.
Source: BSR guideline — diagnosis and treatment of giant cell arteritis British Society for Rheumatology · tier 2, specialty society or college
The other sections of MRCP Part 2
Cardiology · Respiratory medicine · Gastroenterology and hepatology · Neurology · Endocrinology and metabolic medicine · Nephrology · Haematology · Infectious diseases and tropical medicine · Oncology and palliative care · Dermatology · Clinical pharmacology and therapeutics · Clinical sciences and statistics · Acute and critical care medicine
Back to MRCP Part 2